AI-Generated Product Labels: Prop 65, FDA and the Claims That Need a File

Prescribed content, placement and prominence. A model rewriting the statement of identity for readability has changed what the product legally is. Source this from the product master record and treat any diff as a regulatory change.

Ordering rules, mandated common names, and disclosure requirements that do not tolerate paraphrase. This is also the highest-consequence error on the package: an allergen omission is a health event and a recall, not a compliance finding.

Whether a warning is required is an exposure determination; its wording is frequently prescribed. Models both hallucinate warnings onto products that do not need them and omit them from products that do, because they pattern-match on category rather than formulation.

Generated from analysis and formulation data with prescribed formatting and rounding. Any AI involvement here is a data-integrity problem wearing a copywriting costume.

Terms like organic, natural where defined, free-range, non-alcoholic, gluten-free, healthy, and their category equivalents are legal terms with eligibility criteria. Maintain an allow-list of terms this specific product qualifies for and block everything else at generation time.

Permissible only within a defined category and only with substantiation held before publication. The specific hazard is verb drift — supports, maintains and promotes sit in one regime; treats, prevents, reduces the risk of and relieves sit in another.

Recyclable, compostable, carbon-neutral, biodegradable and plant-based all carry substantiation expectations and, in several markets, specific qualification rules. Unqualified general benefit claims are the enforcement staple in this category.

Made-in claims have technical qualification tests that vary by market and by product. A model asked to make the brand story feel local will generate provenance language that the supply chain does not support.

This is the legitimate zone — with the caveat that any objective performance or comparison claim made here still needs substantiation, and that copy written for the website has a habit of migrating onto the carton at the next print run.

Moves from a permitted structure-function framing to an implied disease-prevention claim. Same product, same evidence, different regulatory regime — and now unsubstantiated.

A qualified ingredient claim becomes a product-level certification claim with its own eligibility rules, certifier requirements and percentage thresholds.

A factual statement becomes a defined nutrient-content term with numeric criteria the product may not meet, plus an implied health benefit with no file behind it.

A properly qualified claim loses its qualification and gains an absolute environmental assertion — the single most enforced pattern in green marketing.

An unregulated flourish becomes an origin claim with a technical qualification test the supply chain probably fails.

Our AI only writes the marketplace listing, not the physical package. Does that reduce the exposure?

It changes which regime is in front, not whether one is. Online listings are advertising, so substantiation expectations apply in full, and several labeling regimes reach the digital presentation of a product as well — required disclosures can be expected to appear where the purchase decision is made, and a listing that contradicts the package creates a mismatch that is itself a finding. There is also a practical migration problem that catches teams repeatedly: listing copy is the most reused text a brand owns. It becomes the sell sheet, then the shelf talker, then the next carton, because someone reasonably assumes text already published was already approved. If your listings are AI-drafted and your packaging is not, the boundary between them needs to be a process rather than an assumption.

Can we use AI to check an existing label for compliance rather than to write one?

Review assistance is a much better fit than generation, with two firm limits. First, it is a recall tool, not a precision tool: an assistant is genuinely useful at surfacing candidate issues for a human — a claim with no linked substantiation, a missing element, an inconsistency between the panel and the ingredient statement — and it is unreliable at concluding that a label is fine. Treat every flag as a lead and treat silence as no information. Second, it cannot answer any question that depends on facts outside the document, which includes the entire class of questions that matter most: does this formulation actually qualify for this term, is this exposure below the threshold, is this certification current. A checker that appears to answer those is pattern-matching, and its confident all-clear is the most dangerous output in this article.

Alcohol labels go through their own approval. Does that catch AI errors?

Pre-market label approval regimes for alcohol do catch a specific class of error — prohibited practices, missing mandatory statements, disallowed representations — and they are genuinely a backstop that other categories lack. They are not a compliance program. Approval is granted on what you submitted, so an approved label plus a subsequent copy tweak is an unapproved label, and the tweak is exactly what a brand-voice assistant is used for. Advertising in these categories carries its own separate rules that no label approval touches, and those rules are strict about health-related statements, certain comparative claims and the treatment of alcohol content. The workable model is that approval governs the panel, the claims allow-list governs everything else, and no post-approval edit reaches print without re-review.

What about cosmetics and supplements, where there is no pre-market approval at all?

Those categories carry the highest AI-drafting risk precisely because nothing external will stop a bad claim before it ships. Responsibility for substantiation and for correct labeling sits entirely with the company, and the enforcement that arrives is retrospective — a regulator letter, a competitor challenge, a class action, or a marketplace delisting that costs revenue immediately regardless of merit. The claim-category line is also at its blurriest here, because the permitted vocabulary sits close to the impermissible one and the commercial incentive points across the line. If you sell in these categories, the per-SKU claims allow-list is not a refinement of your process; it is the process, and generation should be constrained to it mechanically rather than by instruction in a prompt.

Our label copy tool is trained on our own approved labels. Isn't that safer?

Safer in tone, not in law, and it introduces a failure mode of its own. A model fine-tuned on your approved corpus will reliably produce text that sounds like your compliant labels, which is a real benefit and also the problem: it generalises claims across products that do not share formulations, certifications or substantiation. The claim that was approved for the product with the clinical file gets applied to the line extension without one; the certification language from the certified SKU appears on the uncertified variant. Because the output matches house style perfectly, it passes the exact review that catches unfamiliar-sounding copy. Product-specific constraints have to be enforced outside the model — an allow-list keyed to the SKU — because no amount of training on compliant text encodes which product a given claim belongs to.

How do we handle a label error we discover after distribution?

Move on two tracks at once and do not let the first delay the second. The regulatory track asks whether the error makes the product misbranded or unsafe, which determines notification duties, correction obligations and whether a market action is required — and it has clocks that begin when you have information, not when you finish deciding. The commercial track covers inventory, rework, retailer notification, listing corrections and the cost allocation with your co-manufacturer. Two things consistently make outcomes worse: treating an allergen or warning omission as a labeling issue rather than a safety issue, and discovering that nobody can say which artwork version is on which lot. Lot-to-artwork traceability is the unglamorous control that determines whether a correction is scoped to one production run or to everything on shelf.